Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered ECG alerts could catch silent heart rhythm problems before they strike

NCT ID NCT06847932

Diagnosis Sponsor: National Defense Medical Center, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an artificial intelligence (AI) system can help doctors spot hidden atrial fibrillation (AF) — a common heart rhythm disorder that raises stroke risk — by flagging suspicious electrocardiograms (ECGs). About 14,700 patients will be randomly assigned to have their ECGs reviewed with or without AI alerts. Those flagged by AI will receive a continuous heart monitor to confirm the diagnosis. The goal is to see if AI can increase early detection of AF and related dangerous rhythms within 90 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 14,726 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 85 days

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients in the inpatient department or the outpatient department * Patients need to have at least one electrocardiogram within one year Exclusion Criteria: * Diagnosis of atrial fibrillation/atrial flutter * History of atrial fibrillation/atrial flutter catheter ablation * Patients with cardiac implantable electronic devices * Any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm * History of received rhythm control medications for atrial arrhythmia, including Class I and Class III antiarrhythmic drugs * Any reasons indicate for anti-coagulant agents, including vitamin K antagonist and non-vitamin K antagonist oral anticoagulant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence (AI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Atrial Premature Complexes cardiac rhythm disease atrial fibrillation prevention target atrial flutter prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence (AI) Atrial arrhythmias Atrial fibrillation (AF) Electrocardiogram Premature atrial complexes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tri-Service General Hospital

    RECRUITING

    Taipei, 114, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.